Tactile Systems Technology (NASDAQ:TCMD) Upgraded at StockNews.com

StockNews.com upgraded shares of Tactile Systems Technology (NASDAQ:TCMD) from a buy rating to a strong-buy rating in a research note issued to investors on Friday morning.

Separately, B. Riley lowered Tactile Systems Technology from a “buy” rating to a “neutral” rating and lowered their price target for the company from $23.00 to $18.00 in a research report on Wednesday, February 19th.

Tactile Systems Technology Stock Performance

NASDAQ:TCMD opened at $13.29 on Friday. The stock has a market cap of $313.44 million, a P/E ratio of 18.99 and a beta of 1.24. The company has a current ratio of 4.36, a quick ratio of 3.80 and a debt-to-equity ratio of 0.11. The stock’s 50-day moving average is $15.89 and its 200-day moving average is $15.82. Tactile Systems Technology has a 1-year low of $11.12 and a 1-year high of $21.10.

Tactile Systems Technology (NASDAQ:TCMD) last posted its quarterly earnings results on Tuesday, February 18th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.09. The firm had revenue of $85.59 million for the quarter, compared to analysts’ expectations of $85.39 million. Tactile Systems Technology had a return on equity of 9.37% and a net margin of 5.79%. Equities research analysts anticipate that Tactile Systems Technology will post 0.7 earnings per share for the current year.

Insider Buying and Selling at Tactile Systems Technology

In related news, VP Kristie Burns sold 4,830 shares of the firm’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $14.65, for a total transaction of $70,759.50. Following the transaction, the vice president now directly owns 84,008 shares of the company’s stock, valued at approximately $1,230,717.20. This trade represents a 5.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Elaine M. Birkemeyer sold 3,778 shares of the firm’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $14.70, for a total value of $55,536.60. Following the transaction, the chief financial officer now directly owns 104,098 shares in the company, valued at approximately $1,530,240.60. This represents a 3.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 19,546 shares of company stock valued at $285,444 in the last 90 days. Corporate insiders own 0.96% of the company’s stock.

Institutional Investors Weigh In On Tactile Systems Technology

A number of large investors have recently made changes to their positions in the business. Mackenzie Financial Corp boosted its holdings in Tactile Systems Technology by 164.1% in the fourth quarter. Mackenzie Financial Corp now owns 36,295 shares of the company’s stock worth $622,000 after acquiring an additional 22,551 shares in the last quarter. PharVision Advisers LLC purchased a new stake in Tactile Systems Technology during the fourth quarter valued at $306,000. Virtus Fund Advisers LLC increased its position in Tactile Systems Technology by 142.0% during the fourth quarter. Virtus Fund Advisers LLC now owns 4,199 shares of the company’s stock valued at $72,000 after acquiring an additional 2,464 shares during the last quarter. Virtus Investment Advisers Inc. increased its position in Tactile Systems Technology by 74.6% during the fourth quarter. Virtus Investment Advisers Inc. now owns 27,931 shares of the company’s stock valued at $478,000 after acquiring an additional 11,930 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new stake in Tactile Systems Technology during the fourth quarter valued at about $239,000. 83.43% of the stock is currently owned by institutional investors.

Tactile Systems Technology Company Profile

Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.